I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
0.8000
-0.0413 (-4.91%)
Mar 31, 2025, 1:25 PM EDT - Market open
I-Mab Employees
I-Mab had 220 employees as of December 31, 2023. The number of employees decreased by 158 or -41.80% compared to the previous year.
Employees
220
Change
-158
Growth
-41.80%
Revenue / Employee
$2,588
Profits / Employee
-$284,357
Market Cap
65.15M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 220 | -158 | -41.80% |
Dec 31, 2021 | 378 | 150 | 65.79% |
Dec 31, 2020 | 228 | 43 | 23.24% |
Dec 31, 2019 | 185 | 51 | 38.06% |
Dec 31, 2018 | 134 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMAB News
- 9 days ago - I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewsWire
- 24 days ago - I-Mab Announces Accelerated Givastomig Phase 1b Study Progress - GlobeNewsWire
- 5 weeks ago - I-Mab to Participate in Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member - PRNewsWire
- 3 months ago - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program - PRNewsWire
- 4 months ago - I-Mab to Participate at the Piper Sandler Healthcare Conference - PRNewsWire
- 4 months ago - I-Mab Reports Third Quarter 2024 Results - PRNewsWire